Last reviewed · How we verify
Changchun marina
Changchun marina is a medication used to treat atrial fibrillation.
Changchun marina is a medication used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Changchun marina |
|---|---|
| Sponsor | Nanjing NingQi Medicine Science and Technology Co., Ltd. |
| Drug class | Anti-arrhythmic |
| Target | Potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
It works by blocking potassium channels in the heart, which helps to regulate heart rhythm. This can help to prevent strokes caused by blood clots that form in the heart due to atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Bradycardia
- Nausea
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Changchun marina CI brief — competitive landscape report
- Changchun marina updates RSS · CI watch RSS
- Nanjing NingQi Medicine Science and Technology Co., Ltd. portfolio CI